Please login to the form below

Not currently logged in
Email:
Password:

Sanofi in TB partnership with Cornell

Sanofi is to enter a research collaboration with Weill Cornell Medical College to identify new anti-infective treatments for the treatment of tuberculosis

Sanofi is to enter a research collaboration with Weill Cornell Medical College to identify new anti-infective treatments for the treatment of tuberculosis (TB).

Research will be focused on drugs that shorten the current course of TB treatment and have the potential to provide effective treatment against strains of TB that are resistant or susceptible to current therapies.

Sanofi will provide 80,000 chemical compounds to Dr Carl Nathan's laboratory at Weill Cornell, the medical college of New York's Cornell University.

The compounds will be screened to assess their ability to inhibit growth of Mycobacterium tuberculosis, the bacterium that causes most cases of TB.

Funding for the screening is provided by the Bill & Melinda Gates Foundation.

"This research collaboration with Weill Cornell will enable us to explore the potential of our existing compound library and pool the extensive knowledge of Dr Nathan and his colleagues," said Elias Zerhouni, president, global R&D at Sanofi. "Should a compound be identified through this collaboration, with Sanofi's drug development expertise, we hope to benefit TB patients worldwide in continuation of our long standing commitment to global health."

30th June 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
eyeforpharma

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....